Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Amgen reports topline results from phase III MENDEL-2 trial

Dec. 19, 2013

Boehringer Ingelheim patents new GPR40 agonists for diabetes

Dec. 18, 2013

Chinese researchers prepare new SGLT2 inhibitors for diabetes

Dec. 18, 2013

Alnylam begins phase II study of ALN-TTRsc for transthyretin-mediated amyloidosis

Dec. 17, 2013

Astrazeneca reports topline results from phase III study of lesinurad in gout

Dec. 17, 2013

FDA advisory committee recommends approval of dapagliflozin

Dec. 16, 2013

SPX-106T lowers cholesterol and triglyceride levels and prevents weight gain in vivo

Dec. 16, 2013

Korean researchers present new antibodies that bind to RANKL for bone disorders

Dec. 16, 2013

FDA committee recommends approval of metreleptin for generalized lipodystrophy

Dec. 13, 2013

Orexigen Therapeutics resubmits NDA for Contrave

Dec. 12, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...